Hop Extract Versus Soy Isoflavone Extract for Menopausal Symptoms (HOPES) (HOPES)
Efficacy of a Full Spectrum Hop (Humulus Lupulus L.) Extract Versus a Soy Extract in Women With Menopausal Symptoms: A Randomized, Double-Blind, Active-Controlled Nutritional Intervention Study (HOPES: Hops On Psychological and Estrogenic Symptoms in Menopause)
HOPES (Hops On Psychological and Estrogenic Symptoms in Menopause) is a randomized, double-blind, active-controlled nutritional intervention study in 120 peri- and postmenopausal women aged 45 to 60 years with moderate to severe menopausal symptoms. For 12 weeks, participants take one capsule per day of either a full spectrum hop (Humulus lupulus L.) extract or a soy isoflavone extract. Both products are marketed dietary supplements, and there is no placebo arm.
The main question is whether the hop extract, which combines prenylated flavonoids with bitter acids, improves the psychological symptoms of menopause (depressive mood, irritability, anxiety, and physical and mental exhaustion) more than the soy extract. The main outcome is the change in the psychological subscale of the Menopause Rating Scale (MRS) from baseline to week 12.
Secondary outcomes include the other MRS domains, anxiety, depressive symptoms, menopause-related quality of life, body composition, and safety.
研究概览
地位
详细说明
Rationale
Many women cannot or do not wish to use menopausal hormone therapy (MHT) and turn to plant-based supplements. Soy isoflavones act mainly through estrogenic mechanisms and have shown a modest effect on vasomotor symptoms, while the evidence for psychological symptoms and sleep is more limited and less consistent. Hop extract has a dual profile: prenylated flavonoids, linked to estrogenic activity, and bitter acids, described in relation to GABAergic neurotransmission and vagal signalling. No direct comparison of the two extracts is available. HOPES tests whether this profile gives the hop extract a differential effect on the psychological domain of menopausal symptoms.
Design
Candidates complete a secure online screening (visit 0). Eligible women attend a baseline visit (visit 1) at the coordinating center, where eligibility is confirmed, assessments and a blood sample are taken, and participants are randomized 1:1 (computer-generated permuted blocks of variable size, stratified by center and menopausal status: perimenopause or postmenopause). Follow-up includes a visit at week 6 (visit 2, in person or remote) and a final visit at week 12 (visit 3).
Capsules and bottles are identical and coded by the sponsor. Participants, the research team and the statistician remain masked until database lock, and an emergency unblinding procedure is available. Adherence is assessed with a capsule diary and a count of returned product, and dietary intake with a 3-day food record at visits 1 and 3.
Assessments
Menopause Rating Scale (MRS), Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Cervantes-31 quality of life scale, and 0-10 visual analogue scales (VAS) for hot flashes, sleep quality and mood; body composition by bioimpedance; and blood tests (liver profile, lipid profile, estradiol and follicle-stimulating hormone) at baseline and week 12.
Analysis
The primary outcome is analyzed in the intention-to-treat population with a mixed model for repeated measures. With 60 participants per arm, the study has 80% power, at a two-sided significance level of 5%, to detect a standardized effect size of about 0.52. Secondary outcomes are tested hierarchically.
A between-group difference of at least 0.5 standard deviations in the change of the MRS psychological subscale is prespecified as clinically relevant.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名：Esmeralda Josa
- 电话号码：+34 914 324 499
- 邮箱：esmeralda.josa@menoclinica.com
学习地点
-
-
Madrid
-
Madrid、Madrid、西班牙、28009
- 招聘中
- Menoclínica by Palacios
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Woman aged 45 to 60 years (both inclusive).
- Perimenopausal or postmenopausal status according to the Stages of Reproductive Aging Workshop +10 (STRAW+10) criteria.
- Moderate to severe menopausal symptoms, defined as a total Menopause Rating Scale (MRS) score of 15 or higher at the baseline assessment prior to randomization.
- Not receiving menopausal hormone therapy (MHT) and not having received it in the previous 3 months.
- Ability to understand and complete the study questionnaires autonomously.
- Written informed consent.
Exclusion Criteria:
- Known allergy or hypersensitivity to soy or any of its derivatives.
- Known allergy or hypersensitivity to hops or to other species of the Cannabaceae family.
- Personal history of breast cancer, endometrial cancer or any other hormone-dependent tumor.
- Genital bleeding of undiagnosed cause.
- Current use, or use in the previous 3 months, of MHT, tibolone, selective estrogen receptor modulators, or dietary supplements or products specifically intended for menopausal symptoms or with a relevant phytoestrogen content, or anticipated need to start any of them during the study.
- Current treatment with antidepressants, anxiolytics, hypnotics, gabapentin or pregabalin.
- Known liver disease or abnormal baseline liver profile (transaminases more than twice the upper limit of normal).
- Moderate or severe renal insufficiency.
- History of venous thromboembolic disease.
- Oral anticoagulant treatment.
- Body mass index (BMI) of 35 kg/m2 or higher.
- Pacemaker or any other implantable electronic device (contraindication for bioimpedance).
- Unstabilized major psychiatric disorder.
- Risky alcohol consumption or substance dependence.
- Simultaneous participation in another clinical trial or intervention study, or participation in one within the previous 30 days.
- Pregnancy or lactation.
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Hop extract
One capsule per day for 12 weeks of MENODUO FullSpectrum, a dry hop (Humulus lupulus L.) strobilus extract, 100 mg/day, providing 10 mg/day of bitter acids and derivatives, 3.5 mg/day of prenylated flavonoids and 2.5 mg/day of xanthohumol. |
100 mg/day orally, one capsule per day for 12 weeks. Provides 10 mg/day of bitter acids and derivatives, 3.5 mg/day of prenylated flavonoids and 2.5 mg/day of xanthohumol.
其他名称：
|
|
有源比较器：Soy extract
One capsule per day for 12 weeks of a dry soy (Glycine max (L.) Merr.) seed extract, 100 mg/day, standardized to at least 40% total isoflavones (at least 40 mg/day) and selected to provide at least 20 mg/day of genistein. |
Description: 100 mg/day orally, one capsule per day for 12 weeks. Standardized to at least 40% total isoflavones (at least 40 mg/day) and at least 20% genistein (at least 20 mg/day). |
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in the psychological subscale score of the Menopause Rating Scale (MRS)
大体时间：Baseline (visit 1) and week 12 (visit 3)
|
The MRS psychological subscale is the sum of items 4 to 7 (depressive mood, irritability, anxiety, and physical and mental exhaustion), each rated from 0 (none) to 4 (very severe). Score range 0 to 16; higher scores indicate greater symptom severity. Change is the week 12 score minus the baseline score. |
Baseline (visit 1) and week 12 (visit 3)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in total MRS score
大体时间：Baseline, week 6 and week 12
|
Sum of the 11 MRS items, each rated 0 to 4. Score range 0 to 44; higher scores indicate greater severity. |
Baseline, week 6 and week 12
|
|
Change in MRS somatic-vegetative subscale score
大体时间：Baseline, week 6 and week 12
|
Sum of items 1, 2, 3 and 11. Score range 0 to 16; higher scores indicate greater severity. |
Baseline, week 6 and week 12
|
|
Change in MRS urogenital subscale score
大体时间：Baseline, week 6 and week 12
|
Sum of items 8, 9 and 10. Score range 0 to 12; higher scores indicate greater severity. |
Baseline, week 6 and week 12
|
|
Change in Generalized Anxiety Disorder-7 (GAD-7) score
大体时间：Baseline and week 12 (optional at week 6)
|
Seven items rated 0 to 3. Score range 0 to 21; higher scores indicate more anxiety symptoms. |
Baseline and week 12 (optional at week 6)
|
|
Change in Patient Health Questionnaire-9 (PHQ-9) score
大体时间：Baseline and week 12 (optional at week 6)
|
Nine items rated 0 to 3. Score range 0 to 27; higher scores indicate more depressive symptoms. |
Baseline and week 12 (optional at week 6)
|
|
Change in the Cervantes Scale global score
大体时间：Baseline and week 12
|
The Cervantes Scale is a 31-item, menopause-specific health-related quality of life questionnaire. Each item is rated from 0 to 5. The global score ranges from 0 to 155; higher scores indicate worse health-related quality of life. Change is the week 12 score minus the baseline score. |
Baseline and week 12
|
|
Change in the Cervantes Scale sexuality domain score
大体时间：Baseline and week 12
|
The sexuality domain of the Cervantes Scale (31-item, menopause-specific health-related quality of life questionnaire) comprises 4 items on sexual function, each rated from 0 to 5. The domain score ranges from 0 to 20; higher scores indicate worse sexual function. Change is the week 12 score minus the baseline score. |
Baseline and week 12
|
|
Change in body fat percentage
大体时间：Baseline and week 12
|
Body fat percentage measured by bioimpedance. |
Baseline and week 12
|
|
Change in estimated visceral fat
大体时间：Baseline and week 12
|
Visceral fat estimate measured by bioimpedance. |
Baseline and week 12
|
|
Change in hot flash intensity (visual analogue scale)
大体时间：Baseline, week 6 and week 12
|
0-10 scale; 0 = no hot flashes, 10 = maximum imaginable intensity. |
Baseline, week 6 and week 12
|
|
Change in sleep quality (visual analogue scale)
大体时间：Baseline, week 6 and week 12
|
0-10 scale; 0 = very poor sleep quality, 10 = excellent sleep quality. |
Baseline, week 6 and week 12
|
|
Change in mood (visual analogue scale)
大体时间：Baseline, week 6 and week 12
|
0-10 scale; 0 = very poor mood, 10 = excellent mood. |
Baseline, week 6 and week 12
|
|
Number of participants with adverse events
大体时间：From baseline to week 12
|
Incidence, nature, severity, duration and relationship to the intervention, including events that lead to interruption of the intervention or withdrawal. |
From baseline to week 12
|
|
Change in liver profile
大体时间：Baseline and week 12
|
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), alkaline phosphatase and bilirubin. |
Baseline and week 12
|
|
Change in lean mass
大体时间：Baseline and week 12
|
Lean mass in kilograms measured by bioimpedance. |
Baseline and week 12
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in lipid profile
大体时间：Baseline and week 12
|
Total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides. |
Baseline and week 12
|
|
Change in serum estradiol
大体时间：Baseline and week 12
|
Serum estradiol concentration. |
Baseline and week 12
|
|
Change in serum follicle-stimulating hormone (FSH)
大体时间：Baseline and week 12
|
Serum FSH concentration. |
Baseline and week 12
|
合作者和调查者
调查人员
- 首席研究员：Silvia Pilar González Rodríguez、Menoclínica by Palacios
出版物和有用的链接
一般刊物
- Heinemann K, Ruebig A, Potthoff P, Schneider HP, Strelow F, Heinemann LA, Do MT. The Menopause Rating Scale (MRS) scale: a methodological review. Health Qual Life Outcomes. 2004 Sep 2;2:45. doi: 10.1186/1477-7525-2-45.
- Palacios S, Ferrer-Barriendos J, Parrilla JJ, Castelo-Branco C, Manubens M, Alberich X, Marti A; Grupo Cervantes. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. Med Clin (Barc). 2004 Feb 21;122(6):205-11. doi: 10.1016/s0025-7753(04)74198-6. Spanish.
- Morimoto-Kobayashi Y, Ohara K, Ashigai H, Kanaya T, Koizumi K, Manabe F, Kaneko Y, Taniguchi Y, Katayama M, Kowatari Y, Kondo S. Matured hop extract reduces body fat in healthy overweight humans: a randomized, double-blind, placebo-controlled parallel group study. Nutr J. 2016 Mar 9;15:25. doi: 10.1186/s12937-016-0144-2.
- Keiler AM, Zierau O, Kretzschmar G. Hop extracts and hop substances in treatment of menopausal complaints. Planta Med. 2013 May;79(7):576-9. doi: 10.1055/s-0032-1328330. Epub 2013 Mar 19.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- HOPES-2026-01
- 6554 (其他标识符：Research Ethics Committee (CEIm), Hospital Universitario de La Princesa)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
IPD 计划说明
Individual participant data will not be shared at this stage. Aggregate results will be published in a peer-reviewed journal.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.